false 0001833214 0001833214 2023-06-29 2023-06-29 0001833214 sabs:CommonStock00001ParValuePerShareCustomMember 2023-06-29 2023-06-29 0001833214 sabs:WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShareCustomMember 2023-06-29 2023-06-29
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): June 29, 2023
 
SAB BIOTHERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
 
 
Delaware
001-39871
85-3899721
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
2100 East 54th Street North
  
Sioux Falls, South Dakota
  
57104
(Address of Principal Executive Offices)
  
(Zip Code)
 
Registrant’s Telephone Number, Including Area Code: 605 679-6980
 
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange on which registered
Common stock, $0.0001 par value per share
  
SABS
  
The NASDAQ Stock Market LLC
Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
  
SABSW
  
The NASDAQ Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
On June 29, 2023, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares entitled to vote at the Annual Meeting was 50,397,762 and there were present 37,522,905 shares at the Annual Meeting in person or by proxy, which represented 74.45% of the outstanding shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction of business.
 
At the Annual Meeting, the shareholders voted to:
 
  (1)
Elect Jeffrey G. Spragens and David Link as Class II directors to serve a three-year term expiring at the 2026 annual meeting of stockholders or until such director’s successor is duly elected and qualified or until such director’s earlier death, resignation, disqualification or removal.
  (2)
Ratify the appointment of Mayer Hoffman McCann P.C. as the independent registered public accounting firm of SAB Biotherapeutics, Inc. for the fiscal year ending December 31, 2023.
 
The voting results on these proposals were as follows:
 
Proposal 1: Election of two Class II directors
 
Director   Votes For   Withheld   Broker Non-Votes  
Jeffrey G. Spragens   30,399,580   403,139   6,720,186  
David Link   30,402,160   400,559   6,720,186  
 
Proposal 2: Ratify the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023
 
Votes For   Votes Against   Abstentions  
37,253,986   33,433   235,486  
 
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
SAB Biotherapeutics, Inc.
       
Date:
July 3, 2023
By:
/s/ Eddie J. Sullivan
     
Eddie J. Sullivan
Chief Executive Officer
 
 
v3.23.2
Document And Entity Information
Jun. 29, 2023
Document Information [Line Items]  
Entity, Registrant Name SAB BIOTHERAPEUTICS, INC.
Document, Type 8-K
Document, Period End Date Jun. 29, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39871
Entity, Tax Identification Number 85-3899721
Entity, Address, Address Line One 2100 East 54th Street North
Entity, Address, City or Town Sioux Falls
Entity, Address, State or Province SD
Entity, Address, Postal Zip Code 57104
City Area Code 605
Local Phone Number 679-6980
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company true
Entity, Ex Transition Period false
Amendment Flag false
Entity, Central Index Key 0001833214
CommonStock00001ParValuePerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol SABS
Security Exchange Name NASDAQ
WarrantsEachExercisableForOneShareOfCommonStockAtAnExercisePriceOf1150PerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol SABSW
Security Exchange Name NASDAQ
SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more SAB Biotherapeutics Charts.
SAB Biotherapeutics (NASDAQ:SABS)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more SAB Biotherapeutics Charts.